Optune Lua is now approved for use concurrently with immune checkpoint inhibitors or docetaxel in adult patients with metastatic NSCLC who have progressed on or after a platinum-based regimen CE ...

Its portable Optune Lua device, with arrays on adhesive patches worn on the chest or back, received a green light for patients that are also being treated with PD-1/PD-L1 inhibitors or the ...

About two-thirds (63.1%) of patients assigned to Optune Lua experienced device-related adverse events — specifically skin-related disorders under transducer arrays. Most events were grade 1 or ...